X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3046) 3046
Publication (544) 544
Book Review (46) 46
Newsletter (28) 28
Book Chapter (11) 11
Newspaper Article (6) 6
Conference Proceeding (2) 2
Dissertation (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2381) 2381
ritonavir (1729) 1729
male (1490) 1490
hiv infections - drug therapy (1458) 1458
index medicus (1436) 1436
pharmacology & pharmacy (1400) 1400
female (1332) 1332
adult (1210) 1210
pharmacokinetics (1046) 1046
infectious diseases (989) 989
middle aged (886) 886
hiv (810) 810
drug interactions (769) 769
protease inhibitors (725) 725
ritonavir - administration & dosage (725) 725
ritonavir - pharmacokinetics (723) 723
drug therapy, combination (692) 692
ritonavir - therapeutic use (683) 683
hiv protease inhibitors - pharmacokinetics (672) 672
lopinavir (627) 627
hiv protease inhibitors - therapeutic use (561) 561
antiretroviral therapy (536) 536
immunology (501) 501
antiviral agents (500) 500
anti-hiv agents - therapeutic use (484) 484
anti-hiv agents - pharmacokinetics (467) 467
hiv protease inhibitors - administration & dosage (464) 464
microbiology (427) 427
anti-hiv agents - administration & dosage (399) 399
virology (393) 393
hiv infections - virology (388) 388
therapy (382) 382
treatment outcome (375) 375
ritonavir - adverse effects (373) 373
drug therapy (360) 360
ritonavir - pharmacology (357) 357
hiv infection (353) 353
saquinavir (351) 351
hiv protease inhibitors - adverse effects (340) 340
viral load (332) 332
hiv-1 - drug effects (328) 328
lopinavir/ritonavir (327) 327
indinavir (323) 323
adolescent (319) 319
safety (310) 310
area under curve (309) 309
efficacy (303) 303
hiv protease inhibitors - pharmacology (298) 298
animals (294) 294
young adult (275) 275
drug administration schedule (273) 273
human immunodeficiency virus--hiv (270) 270
hiv protease inhibitors - blood (263) 263
human-immunodeficiency-virus (262) 262
p-glycoprotein (260) 260
antiretroviral drugs (257) 257
darunavir (257) 257
research (255) 255
anti-hiv agents - adverse effects (254) 254
dosage and administration (254) 254
aged (251) 251
atazanavir (251) 251
hiv-1 (251) 251
ritonavir - blood (249) 249
pharmacology (248) 248
protease inhibitor (246) 246
health aspects (240) 240
analysis (239) 239
atazanavir sulfate (237) 237
metabolism (236) 236
highly active antiretroviral therapy (233) 233
drug combinations (228) 228
hiv infections - blood (228) 228
in-vitro (226) 226
efavirenz (220) 220
combination (217) 217
cd4 lymphocyte count (216) 216
virus diseases (216) 216
infection (214) 214
tenofovir (212) 212
antiretroviral therapy, highly active (207) 207
dose-response relationship, drug (206) 206
nelfinavir (202) 202
proteases (198) 198
sulfonamides - pharmacokinetics (198) 198
hiv infections - metabolism (196) 196
pyrimidinones - pharmacokinetics (192) 192
hiv-infected patients (191) 191
aids (190) 190
article (190) 190
drugs (181) 181
pyridines - pharmacokinetics (180) 180
hiv-1-infected patients (172) 172
aids/hiv (170) 170
sulfonamides - administration & dosage (170) 170
pharmacology/toxicology (169) 169
prospective studies (168) 168
plasma (167) 167
pregnancy (165) 165
saquinavir - pharmacokinetics (160) 160
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3026) 3026
Spanish (25) 25
French (13) 13
Japanese (9) 9
German (8) 8
Chinese (2) 2
Russian (2) 2
Italian (1) 1
Korean (1) 1
Portuguese (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 03/2010, Volume 87, Issue 3, pp. 322 - 329
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 08/2012, Volume 74, Issue 2, pp. 336 - 345
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • In healthy subjects, GSK2248761 was shown to be safe and well tolerated with single doses up to 1200 mg once daily... 
NNRTI | HIV‐1 infection | antiretroviral therapy | drug‐drug interaction | HIV-1 infection | Drug-drug interaction | Antiretroviral therapy | PHARMACOKINETICS | TOLERABILITY | PHARMACOLOGY & PHARMACY | ATAZANAVIR | SIMVASTATIN | drug-drug interaction | PROTEASE INHIBITORS | Fluorobenzenes - pharmacokinetics | Pyrroles - pharmacokinetics | Darunavir | Ethinyl Estradiol - pharmacokinetics | Humans | Pyrrolidinones - pharmacokinetics | Male | Fluorobenzenes - administration & dosage | Indoles - administration & dosage | Lopinavir - pharmacokinetics | Anti-HIV Agents - administration & dosage | Pyrrolidinones - administration & dosage | Tenofovir | Deoxycytidine - pharmacokinetics | Drug Interactions | Pyrroles - administration & dosage | Contraceptives, Oral - administration & dosage | Patient Safety | Atazanavir Sulfate | Contraceptives, Oral - pharmacokinetics | Phosphinic Acids - administration & dosage | Raltegravir Potassium | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Risk Assessment | Simvastatin - administration & dosage | Deoxycytidine - administration & dosage | Phosphinic Acids - pharmacokinetics | Rosuvastatin Calcium | Adenine - pharmacokinetics | Sulfonamides - pharmacokinetics | Cross-Over Studies | Cytochrome P-450 CYP3A - metabolism | Atorvastatin | Cytochrome P-450 CYP2D6 - metabolism | Least-Squares Analysis | Lopinavir - administration & dosage | Pyrimidines - pharmacokinetics | Oligopeptides - administration & dosage | Deoxycytidine - analogs & derivatives | Sulfonamides - administration & dosage | Cytochrome P-450 CYP2D6 Inhibitors | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Heptanoic Acids - pharmacokinetics | Pyridines - pharmacokinetics | Reverse Transcriptase Inhibitors - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Reverse Transcriptase Inhibitors - pharmacokinetics | Heptanoic Acids - administration & dosage | Female | Ethinyl Estradiol - administration & dosage | Androstenes - pharmacokinetics | Double-Blind Method | Ritonavir - administration & dosage | Pyrimidines - administration & dosage | Oligopeptides - pharmacokinetics | Linear Models | Simvastatin - pharmacokinetics | Androstenes - administration & dosage | Adenine - administration & dosage | Organophosphonates - pharmacokinetics | Organophosphonates - administration & dosage | Cytochrome P-450 CYP3A Inhibitors | Ritonavir - pharmacokinetics | Anti-HIV Agents - pharmacokinetics | Indoles - pharmacokinetics | Drug Combinations | Urine | Simvastatin | Drug interactions | Cytochrome P-450 | HIV (Viruses) | Complications and side effects | Analysis | Electrocardiogram | Electrocardiography | DNA polymerases | Ethinyl estradiol | Dosage and administration | EKG | Antiviral agents | Urinalysis | Ritonavir | tenofovir | Cytochrome P450 | Lopinavir | ethinylestradiol | Blood | Infection | non-nucleoside reverse transcriptase inhibitors | Antiviral activity | Drug interaction | Probes | CYP2D6 protein
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 01/2016, Volume 60, Issue 1, pp. 105 - 114
Journal Article
Clinical Pharmacokinetics, ISSN 0312-5963, 10/2017, Volume 56, Issue 10, pp. 1115 - 1124
Journal Article
Clinical Pharmacokinetics, ISSN 0312-5963, 10/2017, Volume 56, Issue 10, pp. 1103 - 1113
Journal Article
AIDS, ISSN 0269-9370, 01/2014, Volume 28, Issue 1, pp. 59 - 66
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 3/2013, Volume 56, Issue 5, pp. 718 - 726
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2015, Volume 63, Issue 4, pp. 805 - 812
Background & Aims Paritaprevir, ombitasvir, and dasabuvir are direct-acting antivirals for treatment of chronic hepatitis C virus (HCV) infection. The aim of... 
Gastroenterology and Hepatology | Direct-acting antiviral agents | Ombitasvir | Chronic hepatitis C | Hepatic impairment | Ritonavir | Paritaprevir | Pharmacokinetics | Dasabuvir | ABT-450/R-OMBITASVIR | TRANSPORTER EXPRESSION | RIBAVIRIN | LIVER-DISEASE | GENOTYPE 1 | THERAPY | CIRRHOSIS | HCV | GASTROENTEROLOGY & HEPATOLOGY | Antiviral Agents - pharmacokinetics | Humans | Middle Aged | Cytochrome P-450 CYP3A Inhibitors - pharmacokinetics | Male | Anilides - pharmacokinetics | Carbamates - administration & dosage | Hepatitis C, Chronic - complications | Carbamates - pharmacokinetics | Dose-Response Relationship, Drug | Uracil - administration & dosage | Ribavirin - administration & dosage | Ribavirin - pharmacokinetics | Female | Drug Therapy, Combination | Liver Function Tests | Cytochrome P-450 CYP3A Inhibitors - administration & dosage | Ritonavir - administration & dosage | Macrocyclic Compounds - pharmacokinetics | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Hepatic Insufficiency - blood | Hepatitis C, Chronic - blood | Sulfonamides - pharmacokinetics | Ritonavir - pharmacokinetics | Anilides - administration & dosage | Macrocyclic Compounds - administration & dosage | Hepatic Insufficiency - etiology | Uracil - pharmacokinetics | Sulfonamides - administration & dosage | Uracil - analogs & derivatives | Antiviral agents | Safety and security measures | Hepatitis C virus | Hepatitis C
Journal Article
Journal Article
Journal Article